Key result
Hormone replacement therapy linked to ~63% lower MI risk in peri- and postmenopausal women.
Why the study?
The incidence of myocardial infarction, cancer, and death in relation to hormone replacement therapy use in peri-/postmenopausal women was evaluated to address clinical outcomes associated with HRT.
Does hormone replacement therapy reduce the incidence of myocardial infarction, cancer, and death in peri-/postmenopausal women?
Cohort (n=5,721)
Does hormone replacement therapy reduce the incidence of myocardial infarction, cancer, and death in peri-/postmenopausal women?
Relative Risk: 0.37 (95% CI 0.15–0.9)
Absolute Event Rate: 0.61% vs 2.2%
In peri-/postmenopausal women, HRT use is associated with a reduced risk of myocardial infarction but an increased risk of cancer, resulting in no net benefit for all-cause mortality.
Should not yet change practice; hypothesis-generating for potential HRT effects on MI risk.
AIM: The goal of this study was to evaluate the incidence of myocardial infarction, cancer and death in relation to use of hormone replacement therapy (HRT). METHODS: Nine years' follow up of an urban cohort of peri-/postmenopausal women was undertaken. Local and national registers were used for retrieval of events. RESULTS: The incidence of myocardial infarction per 1.000 person-years in users and non-users was 0.61 (5/962) and 2.20 (92/4759) respectively, adjusted relative risk (RR) 0.37; 95% confidence interval 0.15-0.90. Rates of mortality from cardiovascular disease and cancer were 0.36 and 1.10, p= 0.058, and 2.60 and 2.09, p=0.360 respectively. In terms of all-cause mortality the adjusted RR was 1.02; 0.69-1.52, incidence of cancer 1.28; 1.01-1.64, breast cancer 1.52; 1.01-2.28 and endometrial cancer 3.61; 1.54-8.46. CONCLUSIONS: Women affirming use of HRT had a lower incidence of myocardial infarction. Further studies are needed to assess whether the absence of effect on total mortality may be accounted for by an increased cancer risk.
No takes yet. Share an insight, caveat, or question.
Hedblad et al. (2002) conducted a cohort in Peri-/postmenopausal (n=5,721). Hormone replacement therapy (HRT) vs. Non-users was evaluated on Incidence of myocardial infarction (RR 0.37, 95% CI 0.15-0.90). Hormone replacement therapy use in peri-/postmenopausal women was associated with a lower incidence of myocardial infarction (RR 0.37; 95% CI 0.15-0.90) compared to non-users.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: